Abstract/Summary:

Excessive MR activation is implicated in the pathogenesis of cardiovascular disease. MR antagonists (MRA) are effective and key guideline-directed therapy in patients with heart failure (HF) with reduced ejection fraction. However, clinical adverse events due to hyperkalaemia and a decline in renal function significantly restricts the treatment. AZD9977 is a novel, non-steroidal selective MR modulator that, compared with MRA, displays a differentiated MR-binding pattern and cofactor recruitment profile, and exerts similar organ protective effects to eplerenone with minimal effects on urinary electrolyte handling.

Authors: A Whittaker, A Kragh, J Hartleib-Geschwindner, A Backlund, P Greasley, M Heijer, M Kjaer, R Unwin, L Wernevik, A Gabrielsen, H Ericsson
Keywords: non-steroidal, MRA, mineralocorticoid receptor modulator
DOI Number: 10.1093/eurheartj/ehz746.0654      Publication Year: 2019

To search for other research papers by topic, keyword, author, or year, please go to our Publications page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.